<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Primary neuroendocrine tumor of breast is a rare tumor, with few cases reported each year and with an incidence less than 1% from all neuroendocrine tumors. In our report we present a case of a postmenopausal woman with a lump in her left breast whose histopathological aspect was strongly suggestive for primary solid neuroendocrine breast carcinoma. Immunohistochemical examination has been done using a panel of seven biomarkers in order to confirm our initial diagnose and both prognostic and predictive factors. We used cromogranin A, synaptophysin and neuron-specific enolase as neuroendocrine biomarkers. Diagnose was proved by a positive reaction in more than 50% of tumor cells for the first two antibodies. Immunophenotype of the tumor (estrogen and progesterone receptor positive, low Ki6 index and no supraexpression of HER2) is consisted with luminal A molecular subtype. The prognosis was good based on clinic-pathological features and immunohistochemical expression. The patient has a good clinical evolution after surgical treatment and adjuvant therapy, with no local recurrence or distant metastasis after 3 years of surveillance.</p></abstract>

Primary neuroendocrine tumor of breast is a rare tumor, with few cases reported each year and with an incidence less than 1% from all neuroendocrine tumors. In our report we present a case of a postmenopausal woman with a lump in her left breast whose histopathological aspect was strongly suggestive for primary solid neuroendocrine breast carcinoma. Immunohistochemical examination has been done using a panel of seven biomarkers in order to confirm our initial diagnose and both prognostic and predictive factors. We used cromogranin A, synaptophysin and neuron-specific enolase as neuroendocrine biomarkers. Diagnose was proved by a positive reaction in more than 50% of tumor cells for the first two antibodies. Immunophenotype of the tumor (estrogen and progesterone receptor positive, low Ki6 index and no supraexpression of HER2) is consisted with luminal A molecular subtype. The prognosis was good based on clinic-pathological features and immunohistochemical expression. The patient has a good clinical evolution after surgical treatment and adjuvant therapy, with no local recurrence or distant metastasis after 3 years of surveillance.

Primary neuroendocrine breast carcinoma, well differentiated

Clinical Service of Pathology, Emergency County Hospital “Sf. Apostol Andrei” Constanţa

Department of Pathology, Faculty of Medicine, “Ovidius” University, Constanţa

ARS Medica Tomitana

{"article-title":"Primary neuroendocrine breast carcinoma, well differentiated"}

Primary neuroendocrine tumor of breast is a rare tumor, with few cases reported each year and with an incidence less than 1% from all neuroendocrine tumors. In...

Primary neuroendocrine breast carcinoma, well differentiated

Pubblicato online: 26 ott 2013

Pagine: 160 - 165

DOI: https://doi.org/10.2478/arsm-2013-0028

Parole chiave
Primary neuroendocrine breast carcinoma, Chromorganin A, Synaptophysin, Hormone receptors

This content is open access.

Primary neuroendocrine breast carcinoma, well differentiated

Pubblicato online: 26 ott 2013

Pagine: 160 - 165

DOI: https://doi.org/10.2478/arsm-2013-0028

Parole chiavePrimary neuroendocrine breast carcinoma, Chromorganin A, Synaptophysin, Hormone receptors

This content is open access.

Parole chiave
Primary neuroendocrine breast carcinoma, Chromorganin A, Synaptophysin, Hormone receptors